EQ-5D-5L Utility | EQ-5D-5L VAS | EORTC QoL | ||||
---|---|---|---|---|---|---|
ßTobit | SE | ßOLS | SE | ßOLS | SE | |
Intercept | 1.092 | 0.101** | 83.911 | 9.531** | 74.268 | 8.717** |
Time of PRO questioning after enrollment into the registry | ||||||
0 months | ref | ref | ref | ref | ref | ref |
2 months | − 0.017 | 0.033 | 4.349 | 3.120 | −0.270 | 2.847 |
4 months | −0.001 | 0.039 | 1.538 | 3.699 | 1.773 | 3.347 |
8 months | − 0.029 | 0.036 | 0.704 | 3.278 | −4.164 | 2.961 |
12 months | − 0.027 | 0.037 | 8.225 | 3.497* | −0.533 | 3.216 |
16 months | 0.004 | 0.040 | 6.400 | 3.714 | 6.568 | 3.384 |
20 months | −0.009 | 0.045 | 1.183 | 4.180 | 2.669 | 3.894 |
24 months | 0.059 | 0.051 | 12.543 | 4.625** | 7.240 | 4.268 |
Age | 0.001 | 0.001 | −0.079 | 0.102 | 0.070 | 0.092 |
Male | 0.018 | 0.021 | 1.719 | 1.947 | −1.069 | 1.791 |
BMI | 0.001 | 0.002 | 0.200 | 0.207 | 0.127 | 0.197 |
Primary tumor localization | ||||||
Colon | ref | ref | ref | ref | ref | ref |
Rectum | −0.006 | 0.021 | 0.189 | 1.916 | 0.201 | 1.750 |
Inoperable primary tumor | 0.007 | 0.025 | 2.245 | 2.283 | 0.657 | 2.063 |
Number of progressions | ||||||
0 | ref | ref | ref | ref | ref | ref |
1 | 0.034 | 0.038 | 7.763 | 3.615* | −1.686 | 3.333 |
≥ 2 | 0.002 | 0.059 | 10.871 | 5.654 | −5.621 | 5.151 |
Number of metastatic localizations | ||||||
0 | ref | ref | ref | ref | ref | ref |
1 | −0.023 | 0.034 | 0.656 | 3.143 | −1.168 | 2.894 |
2 | −0.043 | 0.038 | 0.080 | 3.519 | 0.225 | 3.231 |
≥ 3 | −0.053 | 0.049 | 0.522 | 4.539 | 1.627 | 4.131 |
Palliative treatment line | ||||||
First-line | ref | ref | ref | ref | ref | ref |
Break after first-line | −0.047 | 0.029 | −4.536 | 2.657 | 0.399 | 2.418 |
Second-line or later | −0.053 | 0.042 | −11.939 | 4.000** | −1.377 | 3.725 |
Antibodies | ||||||
None | ref | ref | ref | ref | ref | ref |
EGFR | 0.012 | 0.029 | −2.900 | 2.699 | 0.766 | 2.468 |
VEGF | 0.022 | 0.025 | −2.343 | 2.358 | 3.732 | 2.153 |
Comorbidities | ||||||
Adiposity | −0.010 | 0.043 | 1.318 | 4.063 | 0.577 | 3.707 |
Anemia | −0.055 | 0.045 | −0.436 | 4.394 | 1.463 | 4.061 |
Chronic gastric or bowel disease | −0.015 | 0.039 | −7.434 | 3.742* | −4.851 | 3.378 |
Coronary heart disease | 0.022 | 0.039 | −3.193 | 3.578 | −4.569 | 3.235 |
Heart failure | 0.029 | 0.051 | −1.782 | 4.688 | −2.827 | 4.245 |
Hypertension | −0.072 | 0.022** | −3.202 | 2.074 | −2.377 | 1.904 |
Moderate or severe kidney disease | −0.026 | 0.056 | −0.262 | 5.268 | 1.763 | 5.082 |
Diabetes mellitusa | 0.031 | 0.029 | 1.637 | 2.746 | 2.521 | 2.502 |
Chronic pulmonary disease | −0.074 | 0.041 | 0.388 | 3.924 | 7.996 | 3.709** |
Thyroid disease | −0.041 | 0.036 | 1.108 | 3.385 | 1.788 | 3.108 |
Tumorb | 0.010 | 0.036 | 4.215 | 3.435 | −4.265 | 3.134 |
Disease and treatment related symptoms (EORTC QLQ-C30 symptom scales) | ||||||
Nausea and vomiting | 0.000 | 0.001 | −0.011 | 0.051 | −0.058 | 0.047 |
Fatigue | −0.004 | 0.000** | −0.384 | 0.044** | −0.472 | 0.040** |
Pain | −0.003 | 0.000** | −0.170 | 0.036** | −0.121 | 0.033** |
σ | 0.177 | 0.007** | – | – | – | – |
Pseudo-R2 | 0.035 | – | – | |||
Adjusted R2 | – | 0.386 | 0.485 |